Overview

Detailed Summary

Sanofi India Limited is a listed pharmaceutical company focused on manufacturing and marketing prescription medicines in India, with a strategic emphasis on diabetes care (insulin portfolio) and distribution partnerships for cardiovascular, CNS and oral anti‑diabetic categories; it operates manufacturing sites (notably Goa) and sells through independent distributors across domestic and select export markets.
The company completed a pivotal transformation in 2025: refocusing on insulin, launching a partnership model for legacy brands, and reorganizing around digital and AI‑enabled customer engagement, which management cites as the foundation for sustainable, profitable growth even as transitional effects impacted reported revenue and segmental comparability.
Financially the year shows mixed signals: domestic sales were essentially flat (+1% FY), diabetes insulin domestic volumes grew +6% and Q4 diabetes grew +11%, but exports plunged (-40% FY) driven by Ankleshwar divestment and partnership phasing, while operating expenses were cut ~17% year‑on‑year supporting a marginal PBT increase of +1% for FY25.
Sanofi India retains market leadership in basal insulin (Lantus ~31% market share) and is investing to scale Soliqua and Toujeo via private and public sector access, while RWE and clinical work (LANDMARC, Soliqua Phase IV) provide evidence and KOL advocacy to support uptake and formulary inclusion across public programs and tier‑2/3 outreach.
Corporate returns remain shareholder friendly: management proposed a dividend increase of ~5% versus prior year with EPS of INR 142 and a high payout ratio (~87%), reflecting a capital distribution stance supported by operational efficiency despite transitional top‑line headwinds.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 8,112 Cr
Volatility: Low Risk
P/E Ratio: 19.6
Industry P/E: 32.3
PEG Ratio: 5.4
P/B Ratio: 9.4
52W High: 6,717.50
52W Low: 3,151.05

Sales CAGR

1Y: 0.86%
3Y: -12.02%
5Y: -8.10%
10Y: -1.19%

Profit CAGR

1Y: -31.45%
3Y: -30.74%
5Y: -5.41%
10Y: 3.13%

ROE

TTM: 42.11%
3Y: 51.17%
5Y: 47.47%
10Y: 28.61%

ROCE

TTM: 52.41%
3Y: 63.90%
5Y: 60.71%
10Y: 38.10%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
MARKSANS		176.15	8,621 Cr	22.13	3.21	0.42	13.08	16.13	10.51
PGHL		4931.05	8,533 Cr	27.89	13.77	2.43	49.51	65.17	32.81
SANOFI		3380.10	8,112 Cr	19.65	9.43	3.49	42.11	52.41	25.64
AKUMS		497.00	8,096 Cr	23.92	2.57	0.00	10.07	8.99	6.29
SHILPAMED		420.00	8,093 Cr	50.94	3.32	0.12	6.35	8.41	4.29
JSLL		654.95	7,859 Cr	26.37	22.23	0.17	42.02	46.06	36.87
SUDEEPPHRM		603.60	7,688 Cr	47.19	9.37	0.00	20.63	23.80	17.20
Median: 7 Co.	—	603.60	8,096 Cr	26.37	9.37	0.17	20.63	23.80	17.20

Financial Statements

Upcoming Result Date: Apr 27, 2026

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	515	491	694	511	464	524	515	536
Expenses	393	377	507	374	348	404	397	364
Operating Profit	122	114	187	137	116	120	118	172
OPM %	23.62	23.13	27.01	26.84	24.96	22.84	22.98	32.08
Other Income	16	11	12	-23	-14	2.30	14	3.30
Interest	0.70	0.30	0.40	0.30	0.40	0.40	0.40	0.30
Depreciation	9.10	9.20	10	9.10	9.00	9.00	9.60	9.60
Profit Before Tax	127	115	189	105	92	113	122	165
Tax %	36.37	29.67	27.07	31.10	25.95	27.00	25.29	27.71
Net Profit	81	81	138	72	68	82	91	120
EPS in Rs	53.37	65.95	59.79	59.31	44.81	35.69	39.64	51.89

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Dec 2023	Dec 2024	TTM
Sales	2,851	2,013	2,038
Expenses	2,047	1,522	1,513
Operating Profit	804	491	526
OPM %	28.19	24.38	25.79
Other Income	83	-21	5.30
Interest	1.70	1.50	1.50
Depreciation	40	37	37
Profit Before Tax	846	431	492
Tax %	28.69	27.28	26.62
Net Profit	603	314	361
EPS in Rs	—	—	172.03
Dividend Payout %	63.79	65.20	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Dec 2023	Dec 2024
Equity Capital	23	23
Reserves	992	838
Borrowings	19	19
Other Liabilities	681	732
Total Liabilities	1,715	1,612
Fixed Assets	315	313
CWIP	16	18
Investments	0.00	0.00
Other Assets	1,384	1,281
Total Assets	1,715	1,612

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Dec 2023	Dec 2024
Cash from Operating Activity	230	462
Cash from Investing Activity	38	-180
Cash from Financing Activity	-878	-392
Net Cash Flow	-610	-111

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%
FIIs	6.72%	6.80%	6.31%	6.11%	5.81%	5.78%	5.63%	5.57%	5.61%	5.57%	5.55%	5.64%
DIIs	19.66%	21.69%	22.71%	23.08%	22.79%	22.82%	22.93%	23.02%	23.06%	22.29%	21.31%	21.13%
Public	13.22%	11.11%	10.58%	10.41%	11.00%	11.00%	11.04%	11.01%	10.94%	11.74%	12.74%	12.83%
Total Shareholders	71,513	68,598	62,870	61,849	67,662	66,211	66,401	68,196	66,790	71,395	75,813	75,758

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q4 FY24

Available on Pro Plan